Author:
Meng Xiangmin,Shang Meimei,Wang Qian,Yan Rong,Jiang Kai,Xiang Junai,Liu Wenhui,Li Jian,Wang Di,Xu Juan
Funder
Shandong Cancer Hospital and Institute, Shandong first Medical University, Clinical research and cultivation program
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference48 articles.
1. Guideline Working Committee of Chinese society of clinical oncology. (2021). Guidelines for clinical use of immune checkpoint inhibitors. People's health press.
2. Shaaban, M., Othman, H., Ibrahim, T., Ali, M., Abdelmoaty, M., Abdel-Kawi, A. R., Mostafa, A., El Nakeeb, A., Emam, H., & Refaat, A. (2020). Immune checkpoint regulators: A new era toward promising cancer therapy. Current Cancer Drug Targets, 20(6), 429–460. https://doi.org/10.2174/1568009620666200422081912
3. Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, B. H., Lunning, M., McGettigan, S., McPherson, J., Mohindra, N. A., Naidoo, J., Olszanski, A. J., … Engh, A. (2020). NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230–241. https://doi.org/10.6004/jnccn.2020.0012
4. Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology, 28((suppl_4)), iv119–iv142. https://doi.org/10.1093/annonc/mdx225
5. Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481